Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
Executive Summary
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
You may also be interested in...
Drug Pricing Activity At US FDA May Be Unique To Gottlieb Tenure
Steven Grossman argues that the former commissioner possessed the credentials to be out front on the pricing issue, unlike other recent FDA commissioners and the current holder of the office.
Stability Key For US FDA, But Changes Needed For Consumer Health Are Clear
Some stakeholders in regulated industries are concerned that without a history as a public agency executive, Stephen Hahn could have an unpredictable tenure as FDA commissioner. Still, consumer health industry trade groups note regulatory topics crucial to the industry's growth and consumer safety should be clear.
Stephen Hahn Should Focus On Stability In First Days As US FDA Commissioner, Stakeholders Say
Among Hahn's primary duties should be to reassure staff that he will not be making radical changes and begin working on a priority list, experts told the Pink Sheet.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: